Studies have also shown that LAA closure with devices like the Watchman FLX Pro can reduce the risk of stroke by ...

A recent British study published in European Heart Journal has reignited discussions on the role of sex as a determinant in ...

The pharma is seeking full approval for its anticoagulation reversal drug Andexxa, which the FDA granted accelerated approval ...

Andexxa (andexanet alfa) is approved for the reversal of anticoagulation by Factor Xa inhibitors – Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Pfizer/Bristol-Myers Squibb's Eliquis (apixaban) ...

Prescribing anti-clotting medications to adults younger than age 65 who have atrial fibrillation (AFib) but no other risk ...

For patients with atrial fibrillation who need protection from stroke and other complications after ablation, left atrial ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been recognized as the 2024 ...

People using blood thinners to control their heart rhythm shouldn't expect the medications to head off thinking decli ...

Chisato Izumi, of the National Cerebral and Cardiovascular Center in Suita, Japan. "Since this medication does not require ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...